Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 16/20 | 0.73 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8509933 | 0.84 | DHFR (1.00) | DHFRMAP4K4DCPSHSP90AA1 | |
| SCHEMBL4533676 | 0.84 | DHFR (0.53) | DHFRDCPSHSP90AA1HSP90AB1HRH4 | |
| SCHEMBL4510941 | 0.82 | DHFR (0.64) | DHFRMAP4K4DCPSHRH4 | |
| SCHEMBL3731337 | 0.78 | SRC (0.68) | DHFRDCPSHSP90AA1HSP90AB1 | |
| SCHEMBL4530856 | 0.78 | MAP4K4 (0.68) | DHFRMAP4K4DCPSHRH4 | |
| SCHEMBL4532538 | 0.78 | DHFR (0.62) | DHFRMAP4K4DCPSHRH4 | |
| SCHEMBL8513000 | 0.77 | DHFR (1.00) | DHFRHRH4 | |
| SCHEMBL4527908 | 0.76 | PTPN1 (0.50) | DHFRDCPSHSP90AA1HSP90AB1 | |
| SCHEMBL5489026 | 0.74 | LCK (0.55) | DHFRDCPSHSP90AA1HSP90AB1 | |
| SCHEMBL13888558 | 0.74 | DHFR (0.93) | DHFRMAP4K4DCPSHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | disclosed |
| EP-1812409-A1 | AMINOQUINAZOLINES COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2007-08-01 | — | — | EP | disclosed |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2006-09-21 | — | — | US | disclosed |
| WO-2006050843-A1 | AMINOQUINAZOLINES COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | PTPN5, PTPN1, PTPN7 | DHFR 2071/4885MAP4K4 639/4885DCPS 2920/4885 |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | PTPN5, PTPN1, PTPN7 | DHFR 2071/4885MAP4K4 639/4885DCPS 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.